PolyPid Ltd. Secures Private Placement Funding
Ticker: PYPD · Form: 6-K · Filed: Dec 26, 2024 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $3.22, $4.00, $14.5 million, $27 million, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, financing, shares
TL;DR
PolyPid just raised cash via a private placement with existing investors. Details in the 6-K.
AI Summary
On December 23, 2024, PolyPid Ltd. announced a private placement financing led by existing institutional shareholders. The company will issue 4,493,830 ordinary shares or pre-funded warrants to investors, raising capital for its operations. The filing details the terms of the Securities Purchase Agreement.
Why It Matters
This private placement provides PolyPid with necessary capital, potentially enabling them to advance their drug development pipeline and meet operational expenses.
Risk Assessment
Risk Level: medium — Private placements can indicate a need for capital, and the terms of the deal could impact existing shareholders.
Key Numbers
- 4,493,830 — Shares/Warrants Issued (Represents the total number of securities to be sold in the private placement.)
Key Players & Entities
- PolyPid Ltd. (company) — The company filing the report and conducting the private placement.
- December 23, 2024 (date) — Date the Securities Purchase Agreement was entered into.
- 4,493,830 (number) — Number of ordinary shares or pre-funded warrants to be issued.
FAQ
What is the total amount of capital PolyPid Ltd. expects to raise from this private placement?
The filing does not specify the dollar amount of the private placement, only the number of shares/warrants to be issued.
Who are the lead investors in this private placement?
The filing states the private placement was led by 'existing institutional shareholders' but does not name specific investors.
What is the purpose of this private placement for PolyPid Ltd.?
The filing implies the purpose is to raise capital for the company's operations, though specific use of funds is not detailed.
What is a 'pre-funded warrant' in the context of this filing?
A pre-funded warrant is an alternative to purchasing ordinary shares, allowing investors to acquire shares at a later date, often with immediate voting rights.
When was the Securities Purchase Agreement for this private placement finalized?
The definitive Securities Purchase Agreement was entered into on December 23, 2024.
Filing Stats: 822 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-12-26 10:15:50
Key Financial Figures
- $3.22 — in lieu thereof, at a purchase price of $3.22 per share (the “Ordinary Shares&r
- $4.00 — Ordinary Shares at an exercise price of $4.00 per share. The warrants expire upon the
- $14.5 million — ult in gross proceeds to the Company of $14.5 million. Exercise of the warrants in full would
- $27 million — s in full would result in an additional $27 million in gross proceeds to the Company. The C
- $50,000 — urse certain accountable expenses up to $50,000. The securities described herein (the
- $41 Million — a Concurrent Private Placement of up to $41 Million”. 99.2 Form of Securities Pur
Filing Documents
- ea0225753-6k_polypid.htm (6-K) — 18KB
- ea022575301ex99-1_polypid.htm (EX-99.1) — 22KB
- ea022575301ex99-2_polypid.htm (EX-99.2) — 242KB
- ea022575301ex99-3_polypid.htm (EX-99.3) — 141KB
- ea022575301ex99-4_polypid.htm (EX-99.4) — 97KB
- ea022575301ex99-5_polypid.htm (EX-99.5) — 94KB
- 0001213900-24-112468.txt ( ) — 615KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. POLYPID LTD. Date: December 26, 2024 By: /s/ Dikla Czaczkes Akselbrad Name: Dikla Czaczkes Akselbrad Title: Chief Executive Officer 3